Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887405 | 0.76 | MAPK1 (0.42) | EPHX1TSHRCYP2C19HDAC4 | |
| SCHEMBL887275 | 0.76 | MAPK1 (0.42) | EPHX1TSHRCYP2C19HDAC4 | |
| SCHEMBL887374 | 0.76 | MAPK1 (0.42) | EPHX1TSHRCYP2C19HDAC4 | |
| SCHEMBL31574623 | 0.65 | MAPK1 (0.41) | EPHX1TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL887359 | 0.65 | GBA1 (0.44) | TSHRCYP2C19MEN1KMT2AHTR2B | |
| SCHEMBL21504750 | 0.65 | — | — | |
| SCHEMBL887283 | 0.64 | GBA1 (0.39) | EPHX1TSHRMEN1KMT2AHTR2B | |
| SCHEMBL1103798 | 0.64 | EPHX1 (0.52) | EPHX1TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL1199046 | 0.64 | EPHX1 (0.52) | EPHX1TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL6571126 | 0.64 | TSHR (0.48) | EPHX1TSHRCYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | EPHX1 1098/4885TSHR 2162/4885CYP2C19 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.